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Whether the presence of Candida spp. in lower respiratory tract (LRT) secretions is a
marker of underlying disease, intensive care unit (ICU) treatment and antibiotic therapy or
contributes to poor clinical outcome is unclear. We investigated healthy controls, patients
with proposed risk factors for Candida growth in LRT (antibiotic therapy, ICU treatment with
and without antibiotic therapy), ICU patients with pneumonia and antibiotic therapy and can-
didemic patients (for comparison of truly invasive and colonizing Candida spp.). Fungal pat-
terns were determined by conventional culture based microbiology combined with
molecular approaches (next generation sequencing, multilocus sequence typing) for
description of fungal and concommitant bacterial microbiota in LRT, and host and fungal
biomarkes were investigated. Admission to and treatment on ICUs shifted LRT fungal
microbiota to Candida spp. dominated fungal profiles but antibiotic therapy did not. Com-
pared to controls, Candida was part of fungal microbiota in LRT of ICU patients without
pneumonia with and without antibiotic therapy (63% and 50% of total fungal genera) and of
ICU patients with pneumonia with antibiotic therapy (73%) (p<0.05). No case of invasive
candidiasis originating from Candida in the LRT was detected. There was no common bac-
terial microbiota profile associated or dissociated with Candida spp. in LRT. Colonizing and
invasive Candida strains (from candidemic patients) did not match to certain clades
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withdrawing the presence of a particular pathogenic and invasive clade. The presence of
Candida spp. in the LRT rather reflected rapidly occurring LRT dysbiosis driven by ICU
related factors than was associated with invasive candidiasis.
Introduction
The role of Candida species in the lower respiratory tract (LRT) has been under discussion for
more than half a century [1]. In critically ill intubated and mechanically ventilated patients
Candida spp. are frequently isolated from LRT secretions such as endotracheal aspirates or
bronchoalveolar lavages (BALs) with uncertain significance. In autopsy studies invasive pul-
monary Candida infection was considered to be very rare [2] or even absent [3,4]. On the other
hand, recent studies demonstrated that the presence of Candida spp. in the LRT was associated
with worse clinical outcome [5,6]. It is unclear from these studies whether Candida spp. coloni-
zation of LRT secretions is a marker of underlying disease severity, intensive care unit (ICU)
treatment and antibiotic therapy or in fact contributes to poor clinical outcomes.
As shown previously, culture-based approaches are inadequate to completely understand
the interactions of the host and the microbiome, and culture independent molecular assays are
more efficient in describing microbial communities [7]. Using such techniques, differences
between ICU patients with pneumonia compared to ICU patients without pneumonia (consid-
ered as controls) have been described [8]. However, the clinical significance of detected micro-
organisms and their role in the etiology of pneumonia could not be elucidated as findings were
not compared to subjects with healthy respiratory tract and to subjects with certain risk factors
considered to influence fungal and bacterial microbiota [7–9]. Beside other risk factors, antibi-
otic therapy and treatment on ICUs have been described as risk factors for Candida coloniza-
tion and invasive candidiasis but the influence of antibiotic therapy on Candida within the
LRT has not been investigated [10]. Recently, biomarkers were used to assess Candida pathoge-
nicity, including (1–3)-ß-D Glucan test with high negative predictive value for invasive candi-
diasis or IL-17A and kynurenine levels showing high sensitivity for invasive candidiasis
illustrated by ROC analysis [11,12].
To examine the presence of Candida in the LRT embedded within fungal and bacterial
microbiota we investigated healthy controls, patients with proposed risk factors for Candida
growth in LRT (antibiotic therapy, ICU treatment with and without antibiotic therapy), and
intubated and mechanically ventilated ICU patients with pneumonia and antibiotic therapy.
Furthermore, for comparison of truly invasive Candida spp. and colonizing Candida spp. can-
didemic patients were also included. Results of fungal patterns including data from conven-
tional microbiology combined with molecular approaches (next generation sequencing,
multilocus sequence typing) for description of fungal and concommitant bacterial microbiota
as well as host (kynurenine) and fungal biomarkes ((1–3)-ß-D Glucan) are reported.
Material and Methods
1. Patients
The study protocol of this observational study was approved by the local ethics committee,
Medical University of Graz (approval number 19–322 ex 07/08). Adult patients >18 years of
age were prospectively recruited at the Medical University of Graz and, after giving written
informed consent, were assigned to one of groups 1–4 according to prospectively established
inclusion and exclusion criteria as listed below. Unconscious intubated and mechanically
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ventilated patients were assigned to patient groups 2 or 3b according to the inclusion and
exclusion criteria, had study related tests and were asked for study participation after their
arousal according to approval of the ethical committee. Demographic, clinical and laboratory
data were extracted from charts and computerized databases. Assessment of simplified acute
physiology score (SAPS) changed from SAPS 2 to SAPS 3 during the study period due to modi-
fications in the routinely used ICU clinical database. The study was registered at clinicaltrials.
gov (clinicaltrials.gov identifier: NCT00786903).
Group 1a consisted of healthy adult patients with healthy respiratory tract (i.e. no known
respiratory tract disease or complaints or x-ray indicative of respiratory tract diseases) under-
going elective plastic surgery and not receiving antibiotic therapy other than optional single
shot surgical prophylaxis as clinically indicated. Surgical prophylaxis consisted of single admin-
istration of an antibiotic according to local guidelines 30–60 minutes prior to skin incision.
Exclusion criteria were clinical or radiological or laboratory evidence of current infectious dis-
ease (temperature>38°C, elevated CRP>5mg/dl, leukocytosis>11400/μl, elevated neutro-
philes>78%); antifungal therapy within 8 weeks prior to inclusion; history of pulmonary
disease (e.g. COPD, asthma bronchiale, sarcoidosis, interstitial lung disease, malignant diseases
of the lung); immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc);
malignant hematological or oncological diseases; HIV positivity. To gain access to the lower
respiratory tract without invasive procedures solely for study purpose the local ethics commit-
tee allowed to include these healthy patients while undergoing general anaesthesia and intuba-
tion due to elective surgical procedures (e.g. plastic surgery). This group served as the control
group and was used for comparative data analysis (e.g. influence of antibiotic therapy on indig-
enous bacterial and fungal flora/microbiota within the LRT; comparison of Candida spp. colo-
nization between healthy individuals and critical ill patients described below).
Group 1b consisted of adults with healthy respiratory tract (i.e. no known respiratory tract
disease or complaints or x-ray indicative of respiratory tract diseases) undergoing elective sur-
gery and receiving antibacterial therapy2 days for treatment of extrapulmonary infectious
diseases. Exclusion criteria for group 1b were antifungal therapy within 8 weeks prior to inclu-
sion; history of pulmonary disease (e.g. COPD, asthma bronchiale, sarcoidosis, interstitial lung
disease, malignant diseases of the lung); immunosuppressive therapy (e.g. glucocorticoids,
methotrexate, azathioprin, etc); malignant hematological or oncological diseases; HIV positiv-
ity. Samples from LRT were obtained similar to group 1a. This group was used to assess the
influence of antibiotic therapy on indigenous bacterial and fungal flora/microbiota of the LRT.
Group 2a consisted of non-neutropenic intubated and mechanically ventilated patients
from the medical ICU without community-acquired (CAP), aspiration (ASP), nosocomial
(NAP) or ventilator-associated pneumonia (VAP) according to previous published case defini-
tions and without antibiotic therapy [13–15]. Exclusion criteria were history of pulmonary dis-
ease (e.g. COPD, asthma bronchiale, sarcoidosis, interstitial lung disease, malignant diseases of
the lung), antifungal therapy within 8 weeks prior to inclusion; immunosuppressive therapy
(e.g. glucocorticoids, methotrexate, azathioprin, etc); malignant hematological or oncological
diseases; HIV positivity.
Group 2b patients consisted of non-neutropenic intubated and mechanically ventilated
patients from the medical ICU without CAP, ASP, NAP or VAP according to previous pub-
lished case definitions but with antibiotic therapy for2 days for treatment of extrapulmonary
infections [13–15]. Exclusion criteria were history of pulmonary disease (e.g. COPD, asthma
bronchiale, sarcoidosis, interstitial lung disease, malignant diseases of the lung), antifungal
therapy within 8 weeks prior to inclusion; immunosuppressive therapy (e.g. glucocorticoids,
methotrexate, azathioprin, etc); malignant hematological or oncological diseases; HIV
positivity.
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Group 2a and 2b were used to assess the influence of ICU related factors on bacterial and
fungal flora/microbiota within the LRT and served as comparator groups for comparison with
intubated and mechanically ventilated patients with pneumonia.
Group 3b consisted of non-neutropenic intubated and mechanically ventilated ICU patients
with CAP, ASP, NAP or VAP according to recently published case definitions and antibiotic
therapy [13–15]. X-rays of the lungs were examined by blinded investigators. Exclusion criteria
were antifungal therapy within 8 weeks prior to inclusion; immunosuppressive therapy (e.g.
glucocorticoids, methotrexate, azathioprin, etc); malignant hematological or oncological dis-
eases; HIV positivity. There was no group 3a (“b”refers to antibiotic therapy according to the
other groups).
Group 4 consisted of patients with documented candidemia (i.e. clinical signs of systemic
inflammatory response syndrome with Candida spp. in blood cultures). Exclusion criteria were
immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc); neutropenia,
HIV positivity. This group constituted the proven invasive Candida infection group. Data
from this group were used for comparison reasons.
2. Sampling
2.1. Group 1a and 1b. At the end of the elective surgical procedure and during termina-
tion of general anaesthesia endobronchial secretion (EBS) was obtained through the endobron-
chial tube (to avoid contamination of samples from oral or pharyngeal bacterial and fungal
microbiota during sampling) by the anaesthesiologist and the study physician, captured in a
sterile cup and immediately brought to the inhouse microbiology laboratory. An oral swab was
obtained prior to sampling EBS. In accordance to recent literature showing similar community
compositions by 16s rRNA sequencing between EBS and BAL from single individuals and
according to the local ethical approval (not allowing lavage in group 1) BAL was not performed
in group 1 patients [16].
2.2. Group 2a and 2b. Samples from the LRT were obtained by bronchoscopy through
endotracheal tubes (to avoid contamination of samples from oral or pharyngeal bacterial and
fungal microbiota during sampling) and BAL (20 ml normal saline) of the right lung. Oral
swabs were obtained prior to bronchoscopy.
2.3. Group 3b. Samples from the LRT were obtained within 24 hours of clinically (includ-
ing x-ray) established diagnosis of CAP, ASP, NAP or VAP by bronchoscopy (to avoid con-
tamination of samples from oral or pharyngeal bacterial and fungal microbiota during
sampling) and BAL (20 ml normal saline) through endotracheal tubes and directed to pulmo-
nary infitrates suggestive of CAP, ASP, NAP or VAP. In case of infiltrates in both lungs sam-
ples from both sites were obtained and processed separately. BAL was captured in a sterile cup
and used for routine and study purpose. An oral swab was performed prior to bronchoscopy. A
second bronchoscopy and BAL was performed 4–7 days after the first sampling in patients still
intubated and mechanically ventilated. Samples for calculation of Candida colonization index
were obtained concomitantly to bronchoscopy.
2.4. Group 4. Routine blood cultures obtained from patients in our Department of Inter-
nal Medicine and routinely processed in our inhouse laboratory were observed for Candida
positivity. Candida spp. were subsequently identified by routine microbiological methods
including MALDI-TOF-mass-spectrometry, stored at -70°C and processed as described below.
Respiratory samples from all patients were immediately brought to the inhouse microbiol-
ogy laboratory, aliquoted, processed and remaining samples stored at -70°C until further analy-
sis (e.g. microbiome analysis). Serum samples were obtained from all patients simultaneously
with microbiological sampling, were centrifugated and stored at -70°C until further analysis.
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Three pairs of blood cultures were obtained concomitantly to blood samples mentioned above
in patients with clinical and laboratory signs of systemic inflammatory response syndrome (i.e.
tachycardia, leucocytosis, tachypnea, and temperature>38°C or<36°C), those were all
patients from groups 1b, 2b, 3b and 4. Candida cultures for calculation of the Candida coloni-
zation index (CI) were performed in patient groups 2 and 3b. Swabs from wounds, catheter
insertion sites, perineal region, oropharynx, as well as BAL and urine were cultured for calcula-
tion of CI as described previously [10].
2.5. Comparison of sampling techniques (EBS vs. BAL). Sampling techniques (collection
of endobronchial secretion, EBS, versus BAL) and sterile saline used for BAL were compared in
additional five intubated and mechanically ventilated ICU patients. Prior to routinely sched-
uled bronchoscopy (and BAL) endobronchial secretion was sampled and collected in a sterile
cup. The bronchoscope was then flushed with 10ml of a given bottle of sterile saline used for
subsequent BAL and the fluid was collected in a sterile cup. Then BAL was obtained by bron-
choscopy and the sample collected in a sterile cup. Consequently, we obtained three sterile
cups with fluid samples for bacterial and fungal microbiota comparison of EBS, BAL and sterile
saline used for BAL corresponding to one patient. BAL was additionally processed and cultured
in the routine laboratory if necessary for routine purpose.
3. Processing of fluid samples, swabs and blood cultures
3.1. Quantitative Candida cultures and bacterial cultures. Quantitative Candida cul-
tures and bacterial cultures from respiratory samples were performed by routine microbiolog-
ical procedures. Briefly, samples from LRT were vortexed and 100 μL transferred onto a
Candida CHROMagar (Becton Dickinson, Heidelberg, Germany), chocolate agar, blood agar,
McConkey agar and was plated evenly with a sterile swab. After incubation at 37°C for 48 h in
ambient air, the colonies were counted and classified as C. albicans, C. glabrata, C. krusei, C.
tropicalis, or other Candida spp., according to the color of the colonies and were further identi-
fied by MALDI-TOF-mass-spectrometry. Quantitative bacterial cultures were performed by
routine microbiological procedures.
3.2. Blood cultures. Three pairs of blood culture bottles were drawn as recommended by
local blood culture instructions and incubated at 37°C in an automatic blood culture detection
system (BACTEC1 9240 or BACTEC FX1, Becton Dickinson, Heidelberg, Germany) for 5
days that allows continuous monitoring of blood cultures for microbial growth. Broth from
positive blood culture bottles was Gram-stained and subcultured on specific agars depending
on the Gram stain results. Fungi and/or bacteria were identified by routine microbiological
procedures including API (bioMérieux, Marcy-l’Etoile, France), and peptid nucleic acid (PNA)
FISH tests allowing quick identification of certain microorganisms within 20–90 minutes. Can-
dida isolates were also identified by MALDI-TOF-mass-spectrometry. Isolated strains were
stored at a temperature of -70°C until further analysis (e.g. susceptibility testing, multilocus
sequence typing).
3.3. Urine and swab cultures. Cultures from urine were performed by routine microbio-
logical procedures. Candida isolates were counted and identified by MALDI-TOF-mass-spec-
trometry. Cultures from swabs were performed on Candida CHROMagar (Becton Dickinson,
Heidelberg, Germany) at 37°C for 48 h in ambient air and Candida isolates were counted and
identified as described above.
3.4. Candida colonization index. In patient groups 2 and 3b swabs from wounds, catheter
insertion sites, perineal region, oropharynx, as well as BAL and urine were cultured for calcula-
tion of Candida colonization index as described previously [10].
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4. Antifungal susceptibility testing of Candida species
Candida strains were tested against amphotericin B, flucytosin, fluconazole, voriconazole,
posaconazole, anidulafungin, caspofungin and micafungin using E-test strips according to the
manufacturer’s instructions (bioMérieux, Marcy-l’Etoile, France) and EUCAST guidelines
[17]. Putative mutations in hot spots of the FKS gene complex were determined as described
previously [18].
5. Multilocus sequence typing (MLST)
To determine relatedness of colonizing and invading Candida albicans strains randomly
selected twenty of 25 oral Candida albicans isolates from group 1 as well as randomly selected
22 of 26 blood culture Candida albicans isolates from group 4 were investigated by MLST. Two
of candidemic patients had oral Candida albicans isolates which were also included in the anal-
ysis. Three isolates did not provide adequate PCR results and were excluded from analysis (1
oral colonizing and 2 invasive isolates).
5.1. DNA extraction for MLST. DNA extraction was carried out by using the PrepMan1
Ultra Sample Preparation Reagent (Applied Biosystems, Foster City, CA). 200 μL of PrepMan
Buffer and 1 loop from a pure culture of each sample were mixed thoroughly in 1.5-mL tubes
and heated in boiling water for 12 min. After a 3 min centrifugation step at 16,100g, the DNA-
containing supernatant was decanted and transferred into a new tube.
5.2. Multilocus sequence typing (MLST). 5.2.1. Primer design and PCR: Seven primer
pairs specific for DNA sites encoding housekeeping genes were chosen as recommended previ-
ously [19–21]: AAT1a, (Aspartateaminotrasferase), fragment size 373, chromosome 2, Fwd
5’-ACTCAAGCTAGATTTTTGGC- 3’, Rev 5’-CAGCAACATGATTAGCCC- 3’; AAC1
(Acetyl-coenzyme A carboxylase), fragment size 407, chromose R, Fwd 5’-GCAAGAGAAATT
TTAATTCAATG- 3’, Rev 5’-TTCATCAACATCATCCAAGTG- 3’; ADP1 (ATP-dependent
permease), fragment size 443, chromose 1, Fwd 5’-GAGCCAAGTATGAATGATTTG- 3’, Rev
5’-TTGATCAACAAACCCGATAAT- 3’, PMI1ba, (formerly MPI1b) (Mannose phosphate
isomerase), fragment size 375, chromosome 2, Fwd 5’-ACCAGAAATGGCCATTGC- 3’, Rev
5’-GCAGCCATGCATTCAATTAT- 3’; SYA1 (Alanyl-RNA synthetase), fragment size 391,
chromosome 6, Fwd 5’-AGAAGAATTGTTGCTGTTACTG- 3’, Rev 5’-GTTACCTTTACCAC
CAGCTTT- 3’, VPS13 (Vacuolar protein sorting protein), fragment size 403, chromosome 4,
Fwd 5’-TCGTTGAGAGATATTCGACTT- 3’, Rev 5’-ACGGATGGATCTCCAGTCC- 3’;
ZWF1b, (Glucose-6-phosphate dehydrogenase), fragment size 491, chromosome 1, Fwd 5’-
GTTTCATTTGATCCTGAAGC- 3’, Rev 5’-GCCATTGATAAGTACCTGGAT- 3’. According
to previous literature these genes enable high discriminatory power in C. albicansMLST inves-
tigations [20,21]. Primers were commercially produced by Invitrogen™ Custom DNA Oligos
(life technologies, Carlsbad, CA). The primer stock solution was diluted with PCR-grade water
to obtain a concentration of 10 μM/L. PCR was carried out with total reaction volumes of
50 μL, containing 37 μL water, 5 μL 10x Taq Buffer, 1 μL dNTP Mix, 1 μL Taq DNA Polymer-
ase (5prime, Hilden, Germany), 2 μL of the forward and reverse primer (10 μM) and 2 μL
DNA template. PCRs were performed on an Applied Biotechnologies 2720 Thermal Cycler
(life technologies, Carlsbad, CA). The duration and temperature of the cycles were chosen as
previously described [22].
5.2.2. Purification: The PCR products were purified using the MSB1 Spin PCRapace purifi-
cation system (STRATEC molecular, Berlin, Germany). Each PCR sample was mixed with
250 μL binding buffer and transferred onto the enclosed spin filter. After 3 min centrifugation
at 13,400 g, the filter was removed and transferred into a new tube. 50 μL elution buffer were
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added prior to a further centrifugation step for 1 min at 9,200g. The filter was then discarded,
the supernatant contained the purified PCR product.
5.2.3. Cycle sequencing: Cycle sequencing was arranged using the BigDye1 Terminator v3.1
Cycle Sequencing Kit (life technologies). The primer stock solution was diluted with PCR-
grade water to obtain a concentration of 1.6 μMol/L. Some amplicons, most notably SYA1
products, had low chromatogram signals or a high noise signal. In this case, agarose gel electro-
phoresis was performed. Whether gel electrophoresis revealed narrow bands, the amount of
template was raised. Cycle sequencing was carried out on an Applied Biosystems 2720 Thermal
Cycler. An initial step of 94°C for 18 sec was followed by 25 cycles of 94°C for 15 sec, 50°C for
10 sec and 60°C for 2 min with a final extension step at 60°C for 4 min. Further purification
steps followed the cycle sequencing. The cycle sequencing products were vortexed in a 1.5-mL
tube with 25 μL 98% ethanol (v/v) and 2.5 μL 125 μM EDTA and then centrifuged for 20 min-
utes at a temperature of 4°C at 16,100 g. After discarding the supernatant, 200 μL of 70% etha-
nol (v/v) were added and another centrifugation step for 15 min at a temperature of 4°C at
16,100g was done. Thereafter the supernatant was removed and the pellet was dried in an incu-
bator at 37°C for at least 1 h. Then the pellet was resuspended in 15 μL Applied Biosystems1
Hi-DiTM Formamide (life technologies) and pipetted onto a 96-well plate. Analysis was per-
formed on the Applied Biosystems1 3130 Genetic Analyzer (life technologies).
5.2.4. MLST Data analysis: Analysis of the raw sequencing data succeeded with Applied Bio-
systems DNA Sequencing Analysis Software (life technologies, Carsbad, CA). After analysis
and post-processing, each forward and reverse sequence pair was assembled with the help of
Lasergene1 SeqMan Pro software (DNAStar, Madison, WI). Any assembly was searched auto-
matically and manually for single nucleotide polymorphisms (SNPs). The SNPs were badged
using the IUPAC nucleotide code according to previous literature [23]. Each consensus
sequence was compared with the database on the MLST website to obtain the allele number
(ST—sequence type) and the MLST profile number (DST—diploid sequence type). New alleles
and DSTs were sent to the curator of the MLST website to obtain the allelic and DST numbers.
The 7 matching sequences of each isolate were concatenated and afterwards aligned by means
of muscle (http://drive5.com/muscle/) according to previous literature [24,25]. Our strains
were added to the C. albicansMLST database (calbicans.mlst.net) and they are available using
the following headings: id = 2275–2315 or Sequencer = Buzina Walter. In order to assign the
strains to their clades, an eBURST analysis was performed acording to previous literature [26].
5.2.5. Phylogenetic analysis of MLST data: Evolutionary analyses, using neighbor-joining
and Unweighted Pair Group Method with Arithmetic mean (UPGMAmethod), were con-
ducted in MEGA6 (www.megasoftware.net) [27].
6. Next generation sequencing (NGS)
6.1. DNA isolation and PCR amplification. Fifty-four randomly selected LRT samples
were submitted to NGS-based fungal and bacterial microbiota analyses comprising 8 specimens
from group 1a, 7 from group 1b, 7 from 2a, 6 from 2b and 26 from group 3b. For 10 samples,
the ITS PCR did not produce any amplicons and samples were therefore excluded from analy-
ses for fungal microbiota (4 in group 1a, 2 in group 1b, 4 in group 3b). In one sample the 16S
rRNA gene PCR did not produce any amplicons and this sample was therefore excluded from
analysis of bacterial diversity. For total DNA isolation from 5 mL BAL/EBS samples, Dithio-
threitol (DTT) at a final concentration of 0.15% (w/v) was added, samples were incubated until
dissolved and centrifuged at 4,000g for 30 min. Cells pellets were homogenized in 250 μL PBS
and mixed with 250 μL bacteria lysis buffer in MagnaLyser bead tubes by using the MagnaLyser
Instrument (Roche Diagnostics, Mannheim, Germany) according to manufacturer’s
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instructions. DNA was extracted using the MagNA Pure LC DNA Isolation Kit III (Bacteria,
Fungi) with 25 μL lysozyme (100 mg/mL) (Roche Diagnostics, Mannheim, Germany), 20 μL
Proteinase K (20 mg/mL) and three consecutive freeze-thaw cycles in a MagNA Pure LC 2.0
Instrument according to manufacturer’s instructions. DNA was quantified by quantitative real
time PCR as described previously [28]. 16S rRNA gene hypervariable regions V1-2 (F27-5’-
AGAGTTTGATCCTGGCTCAG-3’, R357-5’CTGCTGCCTYCCGTA-3’) [29,30] were ampli-
fied from total DNA by PCR using FLX 454 one way read (Lib-L kit, Primer A, Primer B, Roche
454 Life Science, Branford, CT, USA) fusion primers bearing the titanium FLX adaptor (5’-
CCATCTCATCCCTGCGTGTCTCCGAC-3’), a key sequence (5’-TCAG-3’), a 10-mer Multi-
plex Identifier (MID) and the target specific forward sequence (5’-AGAGTTTGATCCTGGCTC
AG-3’). The reverse fusion primer sequence was 5’-CCTATCCCCTGTGTGCCTTGGCAGTC-
TCAG-CTGCTGCCTYCCGTA-3’. For each sample a mix of 25 μL containing 1 x Fast Start
High Fidelity Buffer (Roche Diagnostics, Mannheim, Germany), 2.5 U High Fidelity Enzyme
(Roche Diagnostics, Mannheim, Germany), 200μM dNTPs (Roche Diagnostics, Mannheim,
Germany), 0.4μM barcoded primers (Eurofins MWG, Ebersberg, Germany), PCR-grade water
(Roche Diagnostics, Mannheim, Germany) and 6.5ng genomic DNA. PCR was performed in
triplicates. Thermal cycling was of initial denaturation at 95°C for 3 min followed by 35 cycles
of denaturation at 95°C for 45 sec, annealing at 56°C for 45 sec and extension at 72°C for 1 min
with a final extension of 7 min at 72°C. Amplicons were purified according to standard proce-
dures. Amplicon DNA quantification, pooling and sequencing was performed as recently
described [31]. For internal transcribed spacer (ITS) amplification FLX Titanium Fusion prim-
ers with the target specific forward ITS1F 5’-CTTGGTCATTTAGAGGAAGTAA-3’ and reverse
ITS2R 5’-GCTGCGTTCTTCATCGATGC-3’ sequences were used [32]. For ITS PCR the same
PCR mix was run with 50ng total genomic DNA and the cycling conditions as previously
described [32]. Subsequent procedure was performed according to the 16S rRNA gene protocol.
6.2. Phylogenetic analysis. To improve overall analysis quality as well as to avoid OTU
inflation due to sequencing errors data was de-noised using previously published methods
[33]. Additionally, contaminant sequences (such as sequences originating from the human
host, or from other non 16S or ITS sources) were detected and removed by the Decontaminator
with 80% identity and 15% query coverage. Briefly, amplicons were aligned using BLAT [34]
against the greengenes 16S version (09.05.2011) and the UNITE ITS version (15.10.2013) data-
base [35]. respectively. BLAT hits were sorted descending according their percentage of iden-
tity and quality coverage. Amplicons which fall below the specified criteria or with no hit at all
were identified as contaminating sequence and removed. Furthermore, all sequences shorter
than 150 bps containing any ambiguous characters, or not matching to the forward primer
(distance>2) or the multiplexing barcodes were discarded. Subsequently, chimeric sequences
were identified for both datasets with UCHIME [36] and removed. The remaining sequences
after the pre-processing process were assigned to their respective samples by using the 10 bp
barcode preceding the primer. In order to perform sample- and group-wide comparisons,
operational taxonomic units (OTUs) were generated with two distinct phylotyping pipelines of
SnoWMAn (http://SnoWMAn.genome.tugraz.at) [37]. For the 16S dataset OTUs were gener-
ated with an extended Ribosomal Database Project (RDP)-Pyrosequencing approach [38], by
using the integrated RDP pipeline of SnoWMAn. Briefly, all sequences were pooled and aligned
with Infernal (V1.0) using a 16S rRNA secondary structure based model for accurate position
alignment of sequences [39]. The aligned sequences were clustered by complete linkage to
form OTUs with sequence distances ranging from 0% to 5%. For each OTU a representative
sequence was extracted and a taxonomic classification was assigned to it using the RDP Bayes-
ian classifier 2.5 [37]. Finally, the pooled sequences were again separated according to their
sample affiliation. Taxonomic classification and biostatistical analyses reported in this paper
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were performed on the clustering results for 3% distance at a classification confidence thresh-
old of 80%.
Phylogenetic classification of the ITS dataset was done using the advanced BLAT approach
of SnoWMAn. Briefly, unique sequences were aligned with BLAT against the UNITE ITS refer-
ence database version (15.10.2013). Subsequently, the best BLAT hit was used to assign taxo-
nomic classification to each amplicon. Finally, samples were de-uniqued again and samples
which result in the same taxonomic classification were assigned to the same OTU.
6.3. Statistical analysis and vizualization. The analyses were conducted using the statisti-
cal and visualization capabilities of SnoWMAn. Species richness [40] was estimated according
to Chao1 [41]. Additionally, the abundance-based coverage estimator (ACE) [42], evenness
[40], Shannon and Simpson diversity index were calculated. Furthermore, OTUs significantly
changing between the different patient groups were assessed by the R Bioconductor package
edgeR (version 3.2.4). Briefly, the feature matrices (i.e. OTU counts per sample) were imported
into R. All counts were increased by 1 to prevent taking the log from 0 and stored within a
DGEList object. To scale the raw library sizes, the calcNormFactors [43] function was applied
using the relative log expression (RLE) method [44]. Subsequently, a model matrix according
to the experimental design was created. The common dispersion of all biological coefficients of
variation (BCV) averaged over all OTUs, as well as the OTU-specific dispersion of the dataset,
were calculated (estimateGLMTagwiseDisp, estimateGLMTrendedDisp, respectively). Prior to
the likelihood ratio test (glmLRT) [45,46] the read counts for each feature were fit to a negative
binomial generalized log-linear model (glmFit). To account for multiple testing and control of
the Type I error (FDR), p-values were adjusted using a Benjamini-Hochberg method [47].
Only features with an adjusted p-value less than 0.05 were considered as differentially
abundant.
6.4. Association and dissociation of bacterial (16S rRNA gene) and fungal (ITS) commu-
nities. Relationships between bacteria and fungi in the samples of the different patient groups
were calculated as odds ratio as described previously [48]. Briefly, for all bacteria and fungi
pairs a two by two contingency table was created, presenting their presence and absence in the
samples. Based on this information the odds ratio for each pair was calculated using the odds
ratio function of R (package vcd_1.3–1. R version 3.0.3). The odds ratios above 2 were consid-
ered a positive association as this means that the detection of a particular organism with the
other organism is twice as likely as with its absence. In contrast, an odds ratio below 0.5 was
interpreted as negative association.
6.5. Sequence data availability. Sequence data generated for this work can be accessed via
the European Bioinformatics Institute Sequence Read Archive (EBI SRA) under the accession
number ERP008535.
7. Determination of serum (1–3)-ß-D Glucan Assay
Serum (1–3)-ß-D Glucan test was performed according to recently described methods [49].
8. Kynurenine and Tryptophane in LRT samples
Kynurenine and Tryptophane in LRT samples were determined in patient groups 1a, 2b, and
3b as described recently [12].
9. Statistical methods of Candida colonization, death rates, Candida
colonization index, kynurenine and tryoptophan
Statistical analysis was performed using R 3.1.1 (www.r-project.org) and the package cherry
version 0.5–10. Differences in Candida colonization and death rates (intra-hospital, 30-day)
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between groups in general and in all pairwise comparisons were tested by using the Fisher‘s
exact test and corrected multiple pairwise comparisons using the closed testing procedure. Dif-
ferences in Candida colonization index as well as in kynurenine levels, tryptophan levels and
kynurenine/tryptophan ratio in LRT samples were tested by Kruskal-Wallis test. The Kruskal-
Wallis test and Fisher’s exact test was used in Table 1. A p-value of<0.05 was considered statis-
tically significant.
10. Ethics Statement
The study protocol was approved by the ethics committee, Medical University of Graz. All con-
scious patients provided written informed consent prior to study related procedures. Uncon-
scious intubated and mechanically ventilated patients at ICU had study related tests and were
asked for study participation after their arousal according to approval of the ethical committee.
During preparation of study procedures and protocols the type of consent had been discussed
with members of our ethical committee, i.e. to obtain consent from family members or to obtain
retrospective consent from unconscious patients after they return to conscious condition and
the procedure described above was suggested and approved by our local ethical committee.
None of the patients declined to participate after having study related procedures. Samples from
group 1 patients (without pneumonia) were taken for study purpose only. In ICU group 2
patients (without pneumonia) bronchoscopy and sampling of LRT was performed for study pur-
pose only. In ICU group 3b patients (with pneumonia) and ICU patients included for sampling
technique comparison bronchoscopy was performed as clinically indicated and samples were
used for routine and study investigations. The second bronchoscopy in group 3b was routine in
nature or solely for study investigations depending on the clinical course of the patients. Blood
cultures were routine in nature since these cultures were routinely obtained in patients with
SIRS and clinical suspicion of bloodstream infection (all patients from groups 1b, 2b, 3b and 4).
Results
Two hundred-and-two patients were investigated consisting of 87 patients in group 1a (healthy
adults), 18 in group 1b (patients with healthy respiratory tract but with antibiotic therapy for
extrapulmonary infection), 8 in group 2a (non-neutropenic intubated and mechanically venti-
lated ICU patients without antibiotic therapy), 23 in group 2b (non-neutropenic intubated and
mechanically ventilated ICU patients with antibiotic therapy for extrapulmonary infection), 34
in group 3b (non-neutropenic intubated and mechanically ventilated ICU patients with antibi-
otic therapy due to pneumonia), and 32 in group 4 (candidemic patients). Demographic data
are depicted in Table 1. None of patients in group 1a and 1b died during the course of the
study. There was no difference in intrahospital death and 30-day mortality rate between the
ICU groups (38% in group 2a, 39% in group 2b, 32% in group 3b) and the candidemic group 4
(31%) (p = 1 for all comparisons). Two out of eight (25%), 9/23 (39%), and 10/34 (29%)
patients in group 2a, 2b, and 3b had positive (1–3)-ß-D Glucan test results. Despite positive
(1–3)-ß-D Glucan tests none of ICU patients suffered or deceased from invasive fungal infec-
tion as determined by clinical, imaging, laboratory and microbiological investigations (i.e.
detection of Candida spp. in blood, sterile fluids or tissues).
Antibiotic therapy increased the prevalence of Candida spp. in the oral cavity and admission
to ICU increased the prevalence of Candida spp. in the LRT as determined by conventional cul-
ture (p-values in Table 2). In total we cultured 139 Candida albicans, 27 C. glabrata, 4 C. para-
psilosis, 4 C. dubliniensis, 2 C. krusei, 1 C. tropicalis, 1 C. kefyr, 1 C. cerevisiae, and 1 C. boidinii
isolate(s) from LRT, urine, oral and perianal swabs and blood samples. Of those, 26 C. albicans,
2 C. parapsilosis, 1 C. tropicalis, 1 C. glabrata and 1 C. krusei isolate(s) were cultured from
Candida in the Lower Respiratory Tract
PLOS ONE | DOI:10.1371/journal.pone.0155033 May 20, 2016 10 / 29















therapy (n = 23)
3b, ICU,
pneumonia, AB




age (IQR) 49 (40–
57)
58 (49–68) 60 (50–67) 66 (54–78) 60 (50–70) 66 (58–73) <0.001
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0 0 2 (1–2.5) 3 (2–4.5) 2.5 (1–4) n.d. 0.11
SAPS 2/3 (median,
IQR)
n.d. n.d. SAPS 2 (5
patients) 62
(23–68)

















n.d. n.d. 528 (355–
665)
450 (266–556) 296 (168–579) n.d. 0.31
Vasopressor/
Catecholamine
0 0 5 (63%) 16 (70%) 26 /76%) 10 (31%) 0.0012
Proton pump
inhibitor
0 18 (100%) 8 (100%) 22 (96%) 33 (97%) 23 (72%) 0.0034
Sedative(s) 0 0 3 (38%) 18 (78%) 29 (85%) 6 (19%) <0.001
Morphine 0 0 4 (50%) 18 (78%) 30 (88%) 11 (34%) <0.001
Enteral nutrition 0 0 6 (75%) 18 (78%) 24 (71%) 32 (100%) 0.0024
Parenteral nutrition 0 0 0 (0%) 1 (4%) 3 (9%) 3 (9%)β 0.78
Nasogastric tube 0 0 7 (88%) 23 (100%) 31 (91%) 11 (34%) 0.0024
Central venous
catheter
0 0 7 (88%) 22 (96%) 33 (97%) 25 (78%) 0.062




0 0 0 (0%) 1 (4%) 6 (18%) 31 (97%)# 0.001
(Continued)
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blood cultures from group 4 patients and comprised invasive Candida strains. Candida suscep-
tibility testing revealed one Anidulafungin resistant Candida albicans isolate with homozy-
geous FKS S645F mutation. MLST was performed with randomly selected 44 isolates,
comprising 17 orally colonizing isolates from group 1a and 22 invasive isolates obtained from
blood cultures (group 4) as well as 2 oral samples from 2 candidemic patients. Three isolates
did not provide adequate PCR results and were excluded from analysis (1 oral colonizing and 2
invasive isolates). There was no difference in distribution of invasive and colonizing isolates in
different clades as determined by eBURST, neighbour joining or UPGMA analysis (Fig 1).
Since there was no putative invasive Candida clade further MLST typing including Candida
















therapy (n = 23)
3b, ICU,
pneumonia, AB




Intrahospital death 0 0 3 (38%) 9 (39%) 11 (32%) 10 (31%) 0.92




0 0 0 (0%) 0 (0%) 0 (0%) 7 (70%) 0.074
IQR = interquartile range
α = by conventional cultures the following pathogens were found in BALs: E. coli 102CFU/ml (2 patients), Staphylococcus aureus 101CFU/ml (1; this
patients also had positive Influenza B PCR), Enterobacter cloacae 105CFU/ml (1), Pseudomonas aeruginosa 102CFU/ml (1),ß-haemolytic streptococci
group A 103CFU/ml (1), Klebsiella sp. 106CFU/ml (1), Proteus mirabilis 101CFU/ml (1), Candida sp. 1-105CFU/ml (11), Candida sp. with Staph. aureus,
Serratia sp., E. coli 106CFU/ml (1), Candida sp. with Staph. aureus 101CFU/ml (1), Candida sp. with E. cloacae 106CFU/ml (1), 8 patients had negative
cultures (1 of these patients had positive Influenza A H1N1 PCR); in the remaining 4 patients bacteria belonging to the oral cavity were cultured.
* = cardiopulmonary resuscitation (CPR) prior to study inclusion
§ = 5 patients with extrapulmonary infections prior to or concommitantly to pneumonia, 3 patients without any underlying disease except pneumonia
$ = underlying infectious diseases prior to candidemia
& = postsurgical 5, malignant disease 4, bleeding and vascular disease 4, renal failure 1, unspecific clinical deterioration 1
# = 1 patient did not receive antimycotic treatment due to palliative care
β = 3 patients had both enteral and parenteral nutrition
n.d. = not determined
doi:10.1371/journal.pone.0155033.t001
Table 2. Candida positive cultures from the oral cavity, lower respiratory tract (LRT), and theCandida colonization index.




infection, AB therapy (n = 18)
2a, ICU, no AB
therapy (n = 8)
2b, ICU, extrapulmonary
infection, AB therapy (n = 23)
3b, ICU, pneumonia,
AB therapy (n = 34)
Oral cavity positive 25 (29%)* 14 (74%)* 4 (50%) 12 (52%) 20 (59%)*




n.d. n.d. 0.25 0.25 0.25
* significant difference with p-values: group 1a vs. 1b < 0.001. 1a vs. 3b = 0.008
** significant difference with p-values: group 1a vs. 2a = 0.02. 1a vs. 2b < 0.001. 1a vs. 3b < 0.001
n.d. = not done
doi:10.1371/journal.pone.0155033.t002
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Fig 1. Neighbor-joining tree of invasive and colonizingCandida isolates.Red dots = invasiveCandida
isolates; green circles = colonizingCandida isolates from patients without candidemia; red circles = oral
colonizing isolates from patients with candidemia. The percentage of replicate trees in which the associated
taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The tree is
drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the
phylogenetic tree. The evolutionary distances are in the units of the number of amino acid differences per site.
doi:10.1371/journal.pone.0155033.g001
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NGS analysis of EBS, BAL and saline used for BAL showed that saline did not influence
microbiota results (as Candida was not present and fungal content reflecting other fungi was
very low with 6% counts per OTU compared to BAL) and that endobronchial secretions and
bronchoalveolar lavages yielded similar results (S1–S5 Figs).
By NGS analysis the LRT of group 1a, 1b, 2a, 2b, and 3b patients contained 12, 10, 8, 5, 7
fungal genera, respectively (including taxa containing more than 2%; genera below 2% of
sequences pooled). Candida spp. were detected in 0%, 0%, 50%, 63% and 73% of total fungal
genera in the according groups, respectively (Fig 2). The differences of average relative Candida
abundance between groups are shown in Fig 3 (p<0.05 for group 1a and 1b versus all other
groups). The LRT of group 1a, 1b, 2a, 2b, and 3b patients further contained 9, 8, 11, 10, 11 bac-
terial genera (including taxa containing more than 2%; genera below 2% of sequences pooled)
Fig 2. Relative abundance of fungal microbiota in lower respiratory tract samples. Healthy adults (bar group 1a), patients with healthy respiratory
tract but with antibiotic therapy for extrapulmonary infection (bar group 1b), non-neutropenic intubated and mechanically ventilated ICU patients without
antibiotic therapy (bar group 2a), non-neutropenic intubated and mechanically ventilated ICU patients with antibiotic therapy for extrapulmonary infection
(bar group 2b), and patients with antibiotic therapy due to pneumonia (bar group 3b). Fungi are shown at genus level. Yellow bars represent the sum of
Candida sequences across all samples per group related to the total number of detected fungal sequences within each of the groups. By conventional
cultureCandida spp. were detected in 0/8 (group 1a), 0/7 (group 1b), 1/7 (group 2a), 3/6 (group 2b), and 11/26 (group 3b) patients. No other fungi were
cultured.
doi:10.1371/journal.pone.0155033.g002
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(Fig 4). Relative abundances for each fungal and bacterial taxonomic group for each sample are
shown in the Supporting Information file (S1 and S2 Tables). Differences in fungal and bacte-
rial microbiota between various groups (including fungal and bacterial richness, eveness and
diversity indices) are shown in Figs 5 and 6, and in the Supporting Information file (S3–S6
Tables). Associations and dissociations between certain fungal and bacterial genera are shown
in Figs 7–9 and in the Supporting Information file (S7–S11 Tables and S5 and S6 Figs). In
group 2a the presence of Candida spp. was associated with Fusobacteria sp., Gemella sp.,Hae-
mophilus sp., Parvimonas sp., Prevotella sp., Rothia sp., and dissociated with Actinomyces sp.,
Bacteroides sp., Bradyrhizobium sp., Granulicatella sp., Staphylococcus sp. and Veillonella sp. In
group 2b the presence of Candida spp. was associated with Prevotella sp. and Veillonella sp.,
and dissociated withHaemophilus sp. In group 3b the presence of Candida spp. was associated
with Atobium sp., Bacteroides sp., Bradyrhizobium sp., Corynebacterium sp. and Propionibacter-
ium sp., and dissociated with Actinomyces sp., Aeromonas sp., Gemella sp.,Helicobacter sp., Par-
vimonas sp., Pseudomonas sp., Rothia sp., Sphingomonas sp., Staphylococcus sp. In summary,
there was no common bacterial microbiota profile associated or dissociated with Candida spp.
in LRT in the ICU groups and there were no associations or dissociations at all between Can-
dida spp. and bacterial genera in group 1a and 1b. Fungal and bacterial communities of 4
patients with consecutive BAL samples are shown in Figs 10 and 11. Whereas fungal micro-
biota were stable as shown by analysis of first and second BAL sample in 3 of 4 patients bacte-
rial communities differed in consecutive BAL samples in 3 of 4 patients.
Median kynurenine levels in LRT samples did not differ between patients from group 1a,
2b, and 3b, i.e. patients with and without pneumonia (median below the detection limit of
1 μM/L; one patient in group 2b had 1.21 μM/L and one patient in group 3 had 1.51 μM/L;
p>0.05 for all comparisons). Since kynurenine is a metabolite of the essential amino acid
Fig 3. Average relativeCandida abundance in lower respiratory tract samples. Healthy adults (bar group 1a), patients with
healthy respiratory tract but with antibiotic therapy for extrapulmonary infection (bar group 1b), non-neutropenic intubated and
mechanically ventilated ICU patients without antibiotic therapy (bar group 2a), non-neutropenic intubated and mechanically
ventilated ICU patients with antibiotic therapy for extrapulmonary infection (bar group 2b), and patients with antibiotic therapy due
to pneumonia (bar group 3b). Significant differences of average relativeCandida abundance between groups are shown with bars
representing the averageCandida abundance and standard errors in given groups (* = p <0.05 for groups 2a, 2b, 3b versus 1a or
1b).
doi:10.1371/journal.pone.0155033.g003
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tryptophan, we also calculated differences in tryptophan levels and a kynurenine/tryptophan
ratio, to exclude dietary or ICU-treatment related influence (i.e., low kynurenine levels due to
low tryptophan levels). There was no difference between group 2b and 3b in these calculations
(p>0.05 for both comparisons). ICU patients from group 2b (median 6.6 μM/L, interquartile
range [IQR] 1.4–25.8 μM/L) and 3b (median 7.9 μM/L, IQR 1–22.3 μM/L) had significantly
higher tryptophan levels compared to healthy controls (median below the detection limit of
1μM/L) (p<0.001 for both comparisons).
Discussion
Our data show that Candida is part of fungal microbiota of various intubated and mechanically
ventilated ICU patients with and without antibiotic therapy and with and without pneumonia.
Candida appears rapidly in the LRT after admission to an ICU even in patients without
Fig 4. Relative abundance of bacterial microbiota in lower respiratory tract samples. Healthy adults (bar group 1a), patients with healthy respiratory
tract but with antibiotic therapy for extrapulmonary infection (bar group 1b), non-neutropenic intubated and mechanically ventilated ICU patients without
antibiotic therapy (bar group 2a), non-neutropenic intubated and mechanically ventilated ICU patients with antibiotic therapy for extrapulmonary infection
(bar group 2b), and patients with antibiotic therapy due to pneumonia (bar group 3b). Bacteria are shown at genus level. By conventional culture bacteria
were cultured in 5/8 (group 1a), 2/7 (group 1b), 7/7 (group 2a), 3/6 (group 2b), and 13/26 (group 3b) patients.
doi:10.1371/journal.pone.0155033.g004
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evidence of pneumonia. Some previously proposed risk factors for Candida colonization and
infection like admission to and treatment on ICUs including intubation and mechanically ven-
tilation shifted LRT fungal microbiota to Candida spp. dominated fungal profiles; however,
antibiotic therapy did not. As shown previously, culture independent molecular assays can
complement cultivation based findings and clearly extend culture results [8]. Our study is in
line with previous studies confirming the non-sterility of the lung [8]. The shift towards Can-
dida spp. dominated microbiota in ICU patients appeared to develop quickly, since intubated
ICU patients without and with antibiotitic therapy were investigated on median day 2 and 3
after admission to ICU. The highest abundance of Candida (73% of all fungal genera) was
detected in intubated and mechanically ventilated patients with various types of pneumonia
treated with antibiotic therapy. However, the increase was not significantly different to the
other ICU groups with and without antibiotic therapy and without pneumonia. There was no
difference in fungal microbiota in certain pneumonia subtypes and relative abundance of
Fig 5. Bray-Curtis distances between study groups indicating differences in fungal species composition. Distance of zero indicates that groups
are completely similar for every species. Distance of 1 indicates that groups are completely dissimilar and do not share any species. Group 1a, healthy
adults; group 1b, healthy respiratory tract but with antibiotic therapy for extrapulmonary infection; group 2a, non-neutropenic intubated and mechanically
ventilated ICU patients without antibiotic therapy; group 2b, non-neutropenic intubated and mechanically ventilated ICU patients with antibiotic therapy
for extrapulmonary infection; group 3b, non-neutropenic intubated and mechanically ventilated ICU patients with antibiotic therapy due to pneumonia.
doi:10.1371/journal.pone.0155033.g005
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Candida spp. in ASP and VAP compared to NAP (78%, 77% and 43% of all fungal genera;
p>0.05 for all comparisons). In contrast to previous investigations we did not observe a loss of
diversity by antibiotic treatment since subjects from group 1a (healthy adults) and 1b (patients
with healthy respiratory tract but with antibiotic therapy for extrapulmonary infection) as well
as 2a (non-neutropenic intubated and mechanically ventilated ICU patients without antibiotic
therapy) and 2b (non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy for extrapulmonary infection) had similar Shannon diversity indices [16]. In
our study every sample from LRT was obtained through endotracheal tubes even in healthy
subjects. Therefore, contamination of samples from oral or pharyngeal bacterial and fungal
microbiota during bronchoscopy or sampling is unlikely. The absence of Candida spp. within
LRT fungal microbiota of healthy subjects (group 1a) resembles those of previous investiga-
tions [50]. In some previous studies reagents have been analyzed to assess the influence of
reagents on mircobiota results from BALs [50]; however, in other studies this was not done
Fig 6. Bray-Curtis distances between study groups indicating differences in bacterial species composition. Distance of zero indicates that
groups are completely similar for every species. Distance of 1 indicates that groups are completely dissimilar and do not share any species. Group 1a,
healthy adults; group 1b, healthy respiratory tract but with antibiotic therapy for extrapulmonary infection; group 2a, non-neutropenic intubated and
mechanically ventilated ICU patients without antibiotic therapy; group 2b, non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy for extrapulmonary infection; group 3b, non-neutropenic intubated and mechanically ventilated ICU patients with antibiotic therapy due
to pneumonia.
doi:10.1371/journal.pone.0155033.g006
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[28]. Nevertheless, none of the studies investigating also reagents showed that Candida abun-
dance reached>50% as has been found in our bronchoalveolar samples from ICU patients.
Therefore, falsification of our BAL results by fungal content of reagents was very unlikely [50].
In addition, recent literature showed similar community compositions by 16s rRNA sequenc-
ing between endotracheal aspirate and BAL from single individuals [16]. However, we also
compared EBS and BAL in intubated and mechanically ICU patients and obtained similar fun-
gal microbiota compositions in both samples. Candida was absent in saline used for BAL. As
Candida abundance did not increase in BAL samples compared to EBS and since Candida was
not present in saline used for BAL the high abundance of Candida in our ICU patients can not
be attributed to sampling technique or contamination by saline used for BAL.
In our patients the shift towards Candida spp. was not associated with invasive candidiasis
as none of the included ICU patients of group 2 and 3 had candidemia or other invasive fungal
disease. There was no association of Candida dominated LRT microbiota and intrahospital or
30 day overall mortality. However, this finding might be influenced by low sample size.
Fig 7. Associations/dissociations between bacteria and fungi (heatmaps). Relationships (association/dissociation) between
bacteria and fungi in lower respiratory tract samples of non-neutropenic intubated and mechanically ventilated ICU patients without
antibiotic therapy calculated as odds ratios and depicted as heatmap. An odds ratio above 2 was considered a positive association (in
red), an odds ratio below 0.5 was interpreted as negative association (= dissociation, in green). The scale shows odds ratios.
doi:10.1371/journal.pone.0155033.g007
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Certainly, we do not believe that Candida colonization at all is of no relevance in ICU patients
as it has been demonstrated as one major risk factor for invasive candidiasis [10].
There was no common bacterial microbiota profile associated or dissociated with Candida
spp. as assessed by NGS. Previously, favorable growth conditions for Pseudomonas aeruginosa
provided by Candida albicans and vice versa have been reported by investigating microbial
interactions with conventional cultures [51–53]. Culture-independent methods provided a
new perspectives to bacterial and fungal diversity. Since there was discordance between con-
ventional culture based and recent molecular investigations of fungal microbiota previous stud-
ies using conventional fungal cultures solely are no longer reliable [7,8]. Thus, associations of
Candida spp. in the LRT with other microorganisms, microbial interactions, worse clinical out-
come and increased hospital mortality of Candida colonized ICU patients as shown in previous
investigations using conventional Candida cultures are questionable. By NGS analysis we did
not observe an association of Pseudomonas sp. and Candida spp. but found a dissociation in
ICU patients with pneumonia.
Fig 8. Associations/dissociations between bacteria and fungi (heatmaps). Relationships (association/dissociation) between
bacteria and fungi in lower respiratory tract samples of non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy for extrapulmonary infection calculated as odds ratios and depicted as heatmap. An odds ratio above 2 was
considered a positive association (in red), an odds ratio below 0.5 was interpreted as negative association (= dissociation, in green).
The scale shows odds ratios.
doi:10.1371/journal.pone.0155033.g008
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In our study Candida isolates from candidemic patients as well as from colonized patients
did not match with certain Candida clades as determined by phylogenetic MLST analysis. This
indicates that not a single putative invasive Candida clade was responsible for invasive candidi-
asis in candidemic group 4 patients and strengthens the hypothesis that certain host factors are
probably more important for development of invasive candidiasis [10].
Previously, we showed that Candida colonized ICU patients with and without pneumonia
as well as healthy controls had lower serum IL-17A and kynurenine levels compared to patients
with candidemia [12]. Increased kynurenine levels in vaginal lavage have been observed in a
murine model of vulvovaginal candidiasis [54]. In our study kynurenine levels as well as kynur-
enine/tryptophan ratio in LRT did not differ between healthy controls and intubated and
mechanically ventilated ICU patients with Candida positive cultures or Candida dominated
fungal microbiota (with and without pneumonia) suggesting the absence of invasive pulmo-
nary candidiasis in our subjects with Candida in LRT. IL-22 has been determined previously
and showed no differences between patients with and without invasive candidiasis [12]. The
(1–3)-ß-D Glucan test has a high potential to exclude invasive candidiasis based on its negative
Fig 9. Associations/dissociations between bacteria and fungi (heatmaps).Relationships (association/dissociation) between
bacteria and fungi in lower respiratory tract samples of non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy due to pneumonia calculated as odds ratios and depicted as heatmap. An odds ratio above 2 was considered a
positive association (in red), an odds ratio below 0.5 was interpreted as negative association (= dissociation, in green). The scale
shows odds ratios. Asterisks show significant differences (p<0.05; 95% confidence interval) for odds ratios (Fig 9).
doi:10.1371/journal.pone.0155033.g009
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predictive value [11,49]. Twentytwo patients had negative (1–3)-ß-D Glucan tests despite pres-
ence of Candida spp. in LRT in 8 of these patients. Ten patients in pneumonia group 3b had
evelevated serum (1–3)-ß-D Glucan tests. Of these patients 4 had Candida positive LRT cul-
tures and 5 had Candida positive LRT fungal microbiota (of which 3 also had Candida positive
cultures). However, all patients had significantly lower serum IL-17A values compared to can-
didemic patients suggesting Candida colonization in contrast to infection as described previ-
ously [12]. Additionally, the positive predictive value for detection of invasive candidiasis by
(1–3)-ß-D Glucan test is only 72% in ICU patients [11] and we did not find invasive candidia-
sis by culture of blood, body fluids or sterile tissues (as clinically indicated). We therefore
believe that these patients did not suffer from invasive candidiasis.
Previously, one autopsy study showed absence of Candida pneumonia in 77 patients with
Candida spp. growth in tracheal aspirate and/or BAL cultures two weeks before death but
another showed Candida pneumonia in 8% of 25 deceased ICU patients [2,3]. However, in a
third autopsy study 4 investigators presented higly discordant results in assessment of histo-
pathological samples from pneumonia patients. Histopathological examination as the pro-
posed gold standard for diagnosis of Candida pneumonia seemed to suffer from high
interobserver variability and standardization has been requested [55]. Transfer of data from
autopsy analyses to the clinical setting suffers from several limitations including delayed nec-
ropsy, vague correlation of premortem cultures with postmortem histological examinations,
missing postmortem cultures in many cases, and poor correlation of postmortem cultures with
histopathological results in previous studies. In additon there is lack of clarity regarding the sig-
nificance of Candida spp. in lung tissue accompanied by histologic changes of pneumonia but
without the histologic demonstration of invading yeasts into lung tissue [2,3]. Additionally,
lung biopsies are dangerous in intubated and mechanically ventilated patients due to imminent
Fig 10. Relative abundance of fungal microbiota in consecutively sampled patients. Consecutive lower
respiratory tract samples of 4 intubated and mechanically ventilated patients with pneumonia. Fungi are
shown at genus level. Yellow bars representCandida species. VAP = Ventilator associated pneumonia,
ASP = aspiration pneumonia, NAP = nosocomial acquired pneumonia.
doi:10.1371/journal.pone.0155033.g010
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major side effects of this procedure and thus cannot be used in the clinical management of
patients with suspected pulmonary Candida infection [3].
Based on our data including conventional culture, NGS, and host and fungal biomarker
tests we conclude that Candida solely colonized the LRT of our 65 ICU patients. The presence
of Candida spp. in the LRT rather reflected rapidly occurring LRT dysbiosis driven by ICU
related factors than was associated with invasive candidiasis.
Supporting Information
S1 Fig. Fungal microbiota analysis (counts per OTU) of endobronchial secretion (EBS),
bronchoalveloar lavage (BAL) and saline. Counts per OTU of fungal microbiota in lower
respiratory tract samples (endobronchial secretion, EBS; bronchoalveolar lavage, BAL) and
Fig 11. Relative abundance of bacterial microbiota in consecutively sampled patients.Consecutive lower respiratory tract samples of 4 intubated
and mechanically ventilated patients with pneumonia. Bacteria are shown at genus level. Unclassified sequences in sample 304-3B-ASP-0 revealed
Escherichia/Shigella sp. using a confidence threshold of 0.63. Comparison of these sequences with reference sequences using BLAST yielded
uncultured Shigella sp. 16s rRNA genes. Unclassified sequences in sample 313-3B-VAP-0 revealed Enterobacter sp. using a confidence threshold of
0.63. Comparison of these sequences with reference sequences using BLAST yielded uncultured proteobacterium 16s rRNA genes. VAP = Ventilator
associated pneumonia, ASP = aspiration pneumonia, NAP = nosocomial acquired pneumonia.
doi:10.1371/journal.pone.0155033.g011
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saline (NaCl). Results of BAL, EBS and saline are displayed for 5 intubated and mechanically
ventilated ICU patients investigated for comparison of lower respiratory tract sampling tech-
niques (EBS vs. BAL) and saline used for BAL in individual patients.
(PDF)
S2 Fig. Fungal microbiota analysis (relative abundance) of endobronchial secretion (EBS),
bronchoalveloar lavage (BAL) and saline. Relative abundance of fungal microbiota in lower
respiratory tract samples (endobronchial secretion, EBS; bronchoalveolar lavage, BAL) and
saline (NaCl). Results of BAL, EBS and saline are displayed for 5 intubated and mechanically
ventilated ICU patients investigated for comparison of lower respiratory tract sampling tech-
niques (EBS vs. BAL) and saline used for BAL in individual patients.
(PDF)
S3 Fig. Bacterial microbiota analysis (counts per OTU) of endobronchial secretion (EBS),
bronchoalveloar lavage (BAL) and saline. Counts per OTU of bacterial microbiota in lower
respiratory tract samples (endobronchial secretion, EBS; bronchoalveolar lavage, BAL) and
saline (NaCl). Results of BAL, EBS and saline are displayed for 5 intubated and mechanically
ventilated ICU patients investigated for comparison of lower respiratory tract sampling tech-
niques (EBS vs. BAL) and saline used for BAL in individual patients.
(PDF)
S4 Fig. Bacterial microbiota analysis (relative abundance) of endobronchial secretion
(EBS), bronchoalveloar lavage (BAL) and saline. Relative abundance of bacterial microbiota
in lower respiratory tract samples (endobronchial secretion, EBS; bronchoalveolar lavage,
BAL) and saline (NaCl). Results of BAL, EBS and saline are displayed for 5 intubated and
mechanically ventilated ICU patients investigated for comparison of lower respiratory tract
sampling techniques (EBS vs. BAL) and saline used for BAL in individual patients.
(PDF)
S5 Fig. Associations/dissociations between bacteria and fungi (heatmaps) of patient group
1a. Relationships (association/dissociation) between bacteria and fungi in lower respiratory
tract samples of healthy adults (group 1a) calculated as odds ratios and depicted as heatmap.
An odds ratio above 2 was considered a positive association (in red), an odds ratio below 0.5
was interpreted as negative association (= dissociation, in green). The scale shows odds ratios.
There were no associations or dissociations between Candida spp. and bacterial genera.
(PDF)
S6 Fig. Associations/dissociations between bacteria and fungi (heatmaps) of patient group
1b. Relationships (association/dissociation) between bacteria and fungi in lower respiratory
tract samples of patients with healthy respiratory tract but with antibiotic therapy for extrapul-
monary infection (group 1b) calculated as odds ratios and depicted as heatmap. An odds ratio
above 2 was considered a positive association (in red), an odds ratio below 0.5 was interpreted
as negative association (= dissociation, in green). The scale shows odds ratios. There were no
associations or dissociations between Candida spp. and bacterial genera in group 1b.
(PDF)
S1 Table. Relative abundances for each fungal taxonomic group for each sample.
(PDF)
S2 Table. Relative abundances for each bacterial taxonomic group for each sample.
(PDF)
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S3 Table. Differences in fungal microbiota of patient groups. Differences in fungal micro-
biota between various groups. 1a = healthy adults; 1b = patients with healthy respiratory tract
but with antibiotic therapy for extrapulmonary infection; 2a = non-neutropenic intubated and
mechanically ventilated ICU patients without antibiotic therapy; 2b = non-neutropenic intu-
bated and mechanically ventilated ICU patients with antibiotic therapy for extrapulmonary
infection; and 3b = non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy due to pneumonia. Tax = Taxa at genus level; G1 = comparative group 1;
G2 = comparative group 2; raw Counts G1 = observed number of counts in comparative group
1. raw Counts G2 = observed number of counts in comparative group 2. cpm G1 = counts per
million in comparative group 1. cpm G2 = counts per million in comparative group 2. log
FC = log fold change. FDR = false diversity rate.
(PDF)
S4 Table. Differences in bacterial microbiota of patient groups. Differences in bacterial
microbiota between various groups. 1a = healthy adults; 1b = patients with healthy respiratory
tract but with antibiotic therapy for extrapulmonary infection; 2a = non-neutropenic intubated
and mechanically ventilated ICU patients without antibiotic therapy; 2b = non-neutropenic
intubated and mechanically ventilated ICU patients with antibiotic therapy for extrapulmonary
infection; and 3b = non-neutropenic intubated and mechanically ventilated ICU patients with
antibiotic therapy due to pneumonia. Tax = Taxa at genus level; G1 = comparative group 1;
G2 = comparative group 2; raw Counts G1 = observed number of counts in comparative group
1. raw Counts G2 = observed number of counts in comparative group 2. cpm G1 = counts per
million in comparative group 1. cpm G2 = counts per million in comparative group 2. log
FC = log fold change. FDR = false diversity rate.
(PDF)
S5 Table. Fungal microbiota richness, eveness and diversity indices. Fungal microbiota rich-
ness, evenness and diversity of lower respiratory tract samples from study groups. Richness,
Chao1 and ACE (Abundance-based Coverage Estimator) are different indicators of species
richness. SDI (Shannon diversity index) and simpson are indicators of diversity. Kruskal-Wal-
lis-Test was used for calculation of p-values (p-values<0.05 = significant). Groups: 1a = healthy
adults, 1b = patients with healthy respiratory tract but with antibiotic therapy for extrapulmon-
ary infection, 2a = non-neutropenic intubated and mechanically ventilated ICU patients with-
out antibiotic therapy, 2b = non-neutropenic intubated and mechanically ventilated ICU
patients with antibiotic therapy for extrapulmonary infection, and 3b = non-neutropenic intu-
bated and mechanically ventilated ICU patients with antibiotic therapy due to pneumonia.
(PDF)
S6 Table. Bacterial microbiota richness, eveness and diversity indices. Bacterial microbiota
richness, evenness and diversity of lower respiratory tract samples from study groups. Rich-
ness, Chao1 and ACE (Abundance-based Coverage Estimator) are different indicators of spe-
cies richness. SDI (Shannon diversity index) and simpson are indicators of diversity. Kruskal-
Wallis-Test was used for calculation of p-values (p-values<0.05 = significant). Groups:
1a = healthy adults, 1b = patients with healthy respiratory tract but with antibiotic therapy for
extrapulmonary infection, 2a = non-neutropenic intubated and mechanically ventilated ICU
patients without antibiotic therapy, 2b = non-neutropenic intubated and mechanically venti-
lated ICU patients with antibiotic therapy for extrapulmonary infection, and 3b = non-neutro-
penic intubated and mechanically ventilated ICU patients with antibiotic therapy due to
pneumonia.
(PDF)
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S7 Table. Associations/dissociations between bacteria and fungi (odds ratios), group 1a.
Relationships (association/dissociation) between bacteria and fungi in lower respiratory tract
samples of healthy adults (group 1a) calculated and depicted as odds ratios. An odds ratio
above 2 was considered a positive association, an odds ratio below 0.5 was interpreted as nega-
tive association (= dissociation).
(PDF)
S8 Table. Associations/dissociations between bacteria and fungi (odds ratios), group 1b.
Relationships (association/dissociation) between bacteria and fungi in lower respiratory tract
samples of patients with healthy respiratory tract but with antibiotic therapy for extrapulmon-
ary infection (group 1b) calculated and depicted as odds ratios. An odds ratio above 2 was con-
sidered a positive association, an odds ratio below 0.5 was interpreted as negative association
(= dissociation).
(PDF)
S9 Table. Associations/dissociations between bacteria and fungi (odds ratios), group 2a.
Relationships (association/dissociation) between bacteria and fungi in lower respiratory tract
samples of non-neutropenic intubated and mechanically ventilated ICU patients without anti-
biotic therapy (group 2a) calculated and depicted as odds ratios. An odds ratio above 2 was
considered a positive association, an odds ratio below 0.5 was interpreted as negative associa-
tion (= dissociation).
(PDF)
S10 Table. Associations/dissociations between bacteria and fungi (odds ratios), group 2b.
Relationships (association/dissociation) between bacteria and fungi in lower respiratory tract
samples of non-neutropenic intubated and mechanically ventilated ICU patients with antibi-
otic therapy for extrapulmonary infection (group 2b) calculated and depicted as odds ratios.
An odds ratio above 2 was considered a positive association, an odds ratio below 0.5 was inter-
preted as negative association (= dissociation).
(PDF)
S11 Table. Associations/dissociations between bacteria and fungi (odds ratios), group 3b.
Relationships (association/dissociation) between bacteria and fungi in lower respiratory tract
samples of non-neutropenic intubated and mechanically ventilated ICU patients with antibi-
otic therapy due to pneumonia (group 3b) calculated and depicted as odds ratios. An odds
ratio above 2 was considered a positive association, an odds ratio below 0.5 was interpreted as
negative association (= dissociation).
(PDF)
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